Related Experiment Video

Updated: May 12, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death

Shu Bian1, Xiaofeng Sun, Aiping Bai

  • 1Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China.

Plos One
|April 9, 2013
PubMed
Abstract

Insights

Extracellular adenosine triphosphate (ATP) triggers tumor cell death via P2X7 receptor signaling. This study uncovers novel P2X7-dependent pathways that promote cancer cell death, supporting purine-based cancer therapies.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Oncology

Background:

  • Extracellular adenosine triphosphate (ATP) acts as a danger signal, enhancing antitumor immunity and directly killing tumor cells.
  • Chronic ATP exposure induces P2X7 receptor-mediated tumor cell death through incompletely understood mechanisms.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which extracellular ATP induces tumor cell death via the P2X7 receptor.
  • To identify novel signaling pathways regulated by P2X7 in response to extracellular ATP.

Main Methods:

  • Investigated acute ATP exposure effects on tumor cell growth and survival in vitro and in vivo.
  • Utilized P2X7 agonist/antagonist studies and P2X7-deficient cell lines generated via lentiviral shRNA.
  • Analyzed downstream intracellular signaling pathways, including PI3K/AKT and AMPK-PRAS40-mTOR axes.

Main Results:

  • Acute ATP exposure causes rapid cytotoxic effects, inhibiting tumor growth.
  • Confirmed P2X7 receptor as the central mediator of extracellular ATP signaling.
  • Identified two key signaling pathways: P2X7-PI3K/AKT and a novel P2X7-AMPK-PRAS40-mTOR axis.
  • Demonstrated that these pathways disrupt the balance between cell growth and autophagy, leading to tumor cell death.

Conclusions:

  • Defined novel molecular mechanisms underlying P2X7-mediated antitumor effects.
  • Provides a strong rationale for developing purine-based drugs for targeted cancer therapy.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...